niacinamide has been researched along with Hepatic Encephalopathy in 6 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Hepatic Encephalopathy: A syndrome characterized by central nervous system dysfunction in association with LIVER FAILURE, including portal-systemic shunts. Clinical features include lethargy and CONFUSION (frequently progressing to COMA); ASTERIXIS; NYSTAGMUS, PATHOLOGIC; brisk oculovestibular reflexes; decorticate and decerebrate posturing; MUSCLE SPASTICITY; and bilateral extensor plantar reflexes (see REFLEX, BABINSKI). ELECTROENCEPHALOGRAPHY may demonstrate triphasic waves. (From Adams et al., Principles of Neurology, 6th ed, pp1117-20; Plum & Posner, Diagnosis of Stupor and Coma, 3rd ed, p222-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of the present study was to compare the efficacies of transarterial chemoembolization (TACE) combined with sorafenib versus TACE monotherapy for treating patients with advanced hepatocellular carcinoma (HCC)." | 7.80 | Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study. ( Duan, Z; Hertzanu, Y; Hu, H; Liu, S; Long, X; Shi, H; Yang, Z, 2014) |
| "Sorafenib was given at a dose of 400 mg/bid (interrupted only around TACE)." | 6.79 | TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial. ( Bitzer, M; Blondin, D; Dollinger, M; Erhardt, A; Gog, C; Häussinger, D; Kolligs, F; Lammert, F; Ohmann, C; Schott, E; Schuchmann, M; Walter, C; Wege, H, 2014) |
| "The purpose of the present study was to compare the efficacies of transarterial chemoembolization (TACE) combined with sorafenib versus TACE monotherapy for treating patients with advanced hepatocellular carcinoma (HCC)." | 3.80 | Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study. ( Duan, Z; Hertzanu, Y; Hu, H; Liu, S; Long, X; Shi, H; Yang, Z, 2014) |
| "Sorafenib was given at a dose of 400 mg/bid (interrupted only around TACE)." | 2.79 | TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial. ( Bitzer, M; Blondin, D; Dollinger, M; Erhardt, A; Gog, C; Häussinger, D; Kolligs, F; Lammert, F; Ohmann, C; Schott, E; Schuchmann, M; Walter, C; Wege, H, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, H | 1 |
| Duan, Z | 1 |
| Long, X | 1 |
| Hertzanu, Y | 1 |
| Shi, H | 1 |
| Liu, S | 1 |
| Yang, Z | 1 |
| Erhardt, A | 1 |
| Kolligs, F | 1 |
| Dollinger, M | 1 |
| Schott, E | 1 |
| Wege, H | 1 |
| Bitzer, M | 1 |
| Gog, C | 1 |
| Lammert, F | 1 |
| Schuchmann, M | 1 |
| Walter, C | 1 |
| Blondin, D | 1 |
| Ohmann, C | 1 |
| Häussinger, D | 1 |
| Marks, AB | 1 |
| Gerard, R | 1 |
| Fournier, P | 1 |
| Coupe, P | 1 |
| Gautier, S | 1 |
| Hsu, SJ | 1 |
| Hsin, IF | 1 |
| Lin, YL | 1 |
| Chen, YC | 1 |
| Huang, HC | 1 |
| Lee, FY | 1 |
| Lin, HC | 1 |
| Chang, CC | 1 |
| Lee, SD | 1 |
| USAITIS, J | 1 |
| Mancini, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study Evaluating Transarterial Chemoembolization (TACE) in Combination With Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)[NCT00618384] | Phase 2 | 43 participants (Actual) | Interventional | 2008-01-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for niacinamide and Hepatic Encephalopathy
| Article | Year |
|---|---|
TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma, Hepatocellular; Chemoembol | 2014 |
5 other studies available for niacinamide and Hepatic Encephalopathy
| Article | Year |
|---|---|
Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Mod | 2014 |
Sorafenib-induced hepatic encephalopathy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Dose-Response Relationship, Dru | 2009 |
The influence of sorafenib on hepatic encephalopathy and the mechanistic survey in cirrhotic rats.
Topics: Animals; Disease Models, Animal; Hepatic Encephalopathy; Humans; Hypertension, Portal; Liver Cirrhos | 2012 |
[RECOVERY IN 2 CASES OF HEPATIC COMA].
Topics: Adolescent; Ascorbic Acid; Cortisone; gamma-Globulins; Hepatic Encephalopathy; Hepatitis; Hepatitis | 1963 |
[Psychiatric aspects of alcoholism].
Topics: Alcohol Amnestic Disorder; Alcohol Withdrawal Delirium; Alcoholic Intoxication; Alcoholism; Dementia | 1982 |